本报讯 （记者王僖）2月27日晚，科兴生物制药股份有限公司（以下简称"科兴制药"）披露2025年度业 绩快报。经初步核算，2025年，该公司实现营业总收入15.41亿元，同比增长9.54%；归属于母公司所有 者的净利润达1.59亿元，较2024年同期的3148万元大幅增长406.47%。 业绩的爆发式增长，亦得益于其长期坚持的创新研发战略进入成果转化期。近年来，科兴制药公司聚焦 肿瘤、自身免疫性疾病及代谢疾病三大潜力领域，推进差异化管线布局，多个具有"同类首创"（FIC） 或"同类最佳"（BIC）潜力的品种已进入临床关键阶段，为长期价值跃升注入新动能。 （文章来源：证券日报） 对于业绩大幅增长的原因，科兴制药方面表示，主要得益于海外市场的强劲开拓，海外收入实现显著增 长，推动整体营收与利润大幅提升。经过多年布局，科兴制药海外版图已覆盖欧盟、巴西、菲律宾、印 尼等约七十个国家和地区，构建起高效、立体的全球市场网络，核心产品出海表现尤为亮眼。在高附加 值的欧盟市场，该公司与合作伙伴共同推动的白蛋白紫杉醇于2024年获批上市，2025年上半年出口量占 中国同类产品出口总量的47.7%，成为海外核心利润增长点。 ...

时针拨回2018年，赵晨阳大学毕业，没有一丝犹豫，回到父亲创办的精锐智能，成为一名"创二代"。做 行政、管生产、干销售，一年三分之一的时间都在出差。彼时的丽水经开区，已是国内滚动功能部件产 业起步最早、生产最集聚、产业链最完整的产业基地，占据全国40%以上的产能、30%以上的中高端市 场份额。 中新网丽水2月27日电(奚金燕 黄晓俊 商政君)27日，雨水已过，惊蛰未至。浙江丽水经济技术开发区的 厂房里机器声渐次响起，马年春节后的第二个周五，复工复产的热潮在浙西南这片工业热土上持续升 温。 赵晨阳在 篆刻。丽水经开区 供图 浙江精锐智能传动有限公司(以下简称"精锐智能")总经理赵晨阳坐在办公桌前，手中的篆刀在印石上缓 缓游走。窗外，是鳞次栉比的厂房；窗内，石屑如雪花般簌簌落下。几分钟前，他还在车间里查看一批 即将出厂的直线导轨，用仪器检测着微米级的精度。而现在，他沉浸在这方寸之间的艺术世界里，仿佛 换了个人。 30岁的赵晨阳，就这样每天穿梭于两个世界之间——一个是精度以微米计量的工业世界，一个是意趣以 心境丈量的篆刻天地。作为公司总经理，他梦想企业能成为具有国际影响力的中国制造企业；而作为一 枚"创二代"，他把 ...

证券日报网2月25日讯，前沿生物在接受调研者提问时表示，公司不会转型为单一的早期研发授权型企 业，始终坚持以创新为核心，且目前拥有已上市创新药、即将上市的高端仿制药，能够为公司带来持续 现金流，支撑研发创新。本次小核酸管线的BD合作，是公司管线价值实现的一种方式，而非商业模式 的转型。未来在小核酸领域，公司将采取灵活的商业模式，核心是打造产品的临床价值，并根据产品特 点选择最优价值实现路径：一方面积极探索与国际药企的国际化合作，借助全球资源实现产品全球市场 拓展；另一方面，对于与公司长期核心战略强关联、公司具备独特开发优势与能力的管线，将坚定保留 主导权，自主推进研发与开发工作。 ...

2026年开年以来，随着创新成果的商业化落地及全球化运营的深入，复星国际核心主业延续了此前 强劲的增长势头，在文旅、消费、创新药等赛道迎来新突破。 文旅消费作为复星的核心主业之一，马年春节期间多条产品线展现了出强劲的增长势头。其中，上 海豫园商城新春假期累计接待客流近120万人次，同比提升超20%；Club Med国内五家精致"一价全 包"度假村春节核心假期六日平均入住率达90%；三亚·亚特兰蒂斯春节假期九日总营业额突破1.24亿 元，同比增长20%，创下历史最佳春节表现。 与此同时，春节期间，复星的创新药赛道也好消息不断。旗下的生物医药研发平台复宏汉霖宣布其 研发的HLX15-SC（重组抗CD38全人单克隆抗体注射液-皮下注射）1期临床试验申请分别获中国国家药 监局批准和美国食品药品管理局（FDA）批准。据了解，HLX15是达雷妥尤单抗生物类似药，目标市 场潜力较大，2024年全球销售额约128.8亿美元。而在2月22日，中国首个自主研发的利妥昔单抗生物类 似药——汉利康迎来上市七周年，该药曾一举填补了国产CD20单抗的空白，作为复星医药"十年磨一 剑"的成果，其标志着中国生物药研发迈出了从跟随到并跑的关键 ...

Core Insights - The letter from Ganli Pharmaceutical reflects on the challenges and achievements of 2025, emphasizing the importance of resilience and commitment to quality in the pharmaceutical industry [4][5] - The company projects a net profit of 1.1 billion to 1.2 billion yuan for 2025, representing a year-on-year growth of 78.96% to 95.23%, driven by domestic market recovery and international revenue growth [4][5] - Ganli Pharmaceutical is committed to internationalization, with significant milestones achieved in various global markets, including the approval of its insulin product in Ethiopia and a partnership in Brazil [5][6] Financial Performance - The expected net profit for 2025 is between 1.1 billion and 1.2 billion yuan, marking a substantial increase compared to the previous year [4] - The growth is attributed to the recovery of the domestic market, structural optimization, and sustained international revenue [4] Internationalization Efforts - Ganli Pharmaceutical has made significant strides in international markets, with a systematic approach to registration and collaboration [5][6] - The company has entered the Sub-Saharan African market with its insulin product and has established a long-term supply agreement in Brazil worth no less than 3 billion yuan [5] - The approval of Ondibta® in the EU marks a milestone as the first Chinese third-generation insulin to enter the European market, showcasing the company's alignment with international standards [6] Research and Development - The company continues to invest in R&D, focusing on metabolic diseases with several innovative pipelines advancing to critical clinical stages [6][7] - Ongoing projects include GLP-1 receptor agonists and long-acting insulin formulations, with research findings being published in international academic forums [6][7] Future Outlook - Ganli Pharmaceutical aims to maintain a steady pace in its internationalization strategy while enhancing its R&D capabilities to meet global market demands [7] - The company is committed to contributing to the global biopharmaceutical industry and providing reliable treatment options for patients [7]

Group 1: Company Performance - Haiwang Bio (code: 000078.SZ) expects a net loss attributable to shareholders of 490 million to 600 million yuan for the year 2025, compared to a loss of 1.19 billion yuan in the previous year, indicating a continuous narrowing of losses for two consecutive years [1] - The company plans to focus on core business and asset integration by divesting 24 long-term loss-making subsidiaries, which is expected to impact net profit by 110 million to 150 million yuan this period [3] - The company anticipates goodwill impairment of 120 million to 150 million yuan, significantly lower than previous periods, indicating a gradual release of prior goodwill risks [3] Group 2: Industry Overview - The pharmaceutical distribution industry is undergoing a deep adjustment, with a decline in hospital and pharmacy terminal sales by 5.7% and 0.4% respectively in the first half of 2025 [2] - The new stage of centralized procurement emphasizes "stabilizing clinical use, ensuring quality, and countering internal competition," leading to structural adjustments in the procurement mechanism [2] Group 3: Strategic Transformation - 2025 is a critical year for Haiwang Bio's strategic transformation, with short-term business structure optimization and cost control pressures affecting performance [3] - The company is enhancing its core capabilities through collaboration with leading brands in the medical device sector and expanding value-added services [4] - The focus on high-margin industrial products and innovative research and development is expected to drive long-term growth, with a shift towards a "product + service" integrated business model [4][5] Group 4: Future Outlook - The company is expected to benefit from industry policy dividends and the implementation of its strategic initiatives, with a potential performance inflection point in 2026 [5] - The medical device sector will continue to deepen partnerships with top brands, aiming to expand its commercial platform to a "billion-level" target [5] - The company plans to accelerate the development of core pipelines and expand its matrix of products undergoing consistency evaluation, aiming to cultivate new profit growth points [7]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved net sales of EUR 11.3 billion, reflecting a growth of 13.3% year-over-year [6][12] - For the full year 2025, total sales reached EUR 43.6 billion, representing a 9.9% growth at constant exchange rates, which is at the upper end of the guidance [14][15] - Business EPS growth was strong at 26.7%, indicating effective operational leverage [12] - Business gross margin expanded by 1.8 percentage points to 77.5%, driven by a favorable product mix and operational efficiencies [14] Business Line Data and Key Metrics Changes - Newly launched medicines and vaccines generated EUR 5.7 billion in sales, with a growth of 34% in 2025 [4][6] - Dupixent sales reached EUR 4.2 billion in Q4 and EUR 15.7 billion for the full year, with over 30% increase in patient numbers [7][8] - Beyfortus sales grew by 9.5% to EUR 1.8 billion, driven by geographic expansion [8][9] Market Data and Key Metrics Changes - The company maintained leadership in influenza and RSV vaccines, with full-year sales of EUR 7.9 billion [8] - The U.S. market share for influenza vaccines increased, particularly with Fluzone High-Dose and Flublok [8] - Beyfortus has protected over 11 million babies in more than 45 countries, preventing an estimated 200,000 hospitalizations [9] Company Strategy and Development Direction - The company is transitioning into an R&D-driven, AI-powered biopharma entity, focusing on business development and M&A opportunities [4] - Strategic acquisitions, including Vicebio and Dynavax Technologies, are aimed at enhancing the vaccine portfolio and expanding into older adult markets [9][10][17] - The company plans to continue investing in manufacturing capacity to meet growing patient demand [14] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 to deliver high single-digit growth in sales and business EPS to grow slightly faster than sales [18] - The company anticipates a decline in vaccine sales in 2026 but expects gross margin expansion to continue [18] - Management highlighted the importance of maintaining a strong capital structure and financial flexibility for future growth opportunities [16] Other Important Information - The company completed a EUR 5 billion share buyback program and proposed a 5% increase in dividends for the 31st consecutive year [17] - The company aims for a free cash flow of at least 20% of net sales in the medium term, with a strong cash flow generation of EUR 8.1 billion in 2025 [15] Q&A Session Summary Question: Can you elaborate on the Dupixent rollout and its competition? - Management reported strong performance with 25% growth year-over-year for Dupixent, driven by new indications like CSU and COPD [30][31] - The penetration rates for Dupixent in AD and CSU are still low, indicating room for market growth [32] Question: What is the outlook for Beyfortus in 2026? - Beyfortus had a 9% increase in 2025, with expectations for continued geographic expansion [34][35] Question: What are the prospects for Amlitelimab? - Management remains confident in Amlitelimab's potential, emphasizing its novel mechanism and the importance of data-driven decisions [39][41] Question: Can you provide details on the Kaposi sarcoma case related to Amlitelimab? - Management clarified that Kaposi sarcoma is associated with herpes virus and is not considered a significant concern for Amlitelimab [46][49] Question: What is the capital allocation strategy moving forward? - The company plans to dynamically allocate resources based on value, with an increase in business development activity expected [60][75]

Core Viewpoint - Tonghua Dongbao (600867) is expected to achieve a net profit of approximately 1.242 billion yuan and a net profit of approximately 402 million yuan after deducting non-recurring gains and losses in 2025, marking a significant turnaround from previous losses and a substantial recovery in performance [1] Group 1: Financial Performance - In 2025, the company anticipates a significant recovery in its financial performance, with both net profit and adjusted net profit turning positive compared to the previous year [1] - The company’s insulin similar products are projected to drive major growth, with annual sales expected to increase by over 100% year-on-year, contributing to a balanced development of its product structure [1][2] Group 2: Market Position and Strategy - Tonghua Dongbao has achieved significant improvements in market share, ranking second in the industry for human insulin and insulin similar products, with a market share of 45.5% for human insulin, maintaining the leading position domestically [2] - The company is focusing on enhancing its domestic insulin business, optimizing product structure, and expanding market share while accelerating its internationalization strategy [1][2] Group 3: Product Development and Innovation - The company has made substantial progress in international product registration, with various insulin formulations and GLP-1 products receiving approvals in multiple countries, including the U.S., Dominican Republic, and Indonesia [3] - Several R&D projects have achieved important clinical milestones, including the completion of Phase III trials for semaglutide and positive results for other diabetes-related products [4] Group 4: Shareholder Engagement - The controlling shareholder, Dongbao Industrial Group, has increased its stake in the company by investing 228 million yuan to acquire 1.42% of the shares, reflecting confidence in the company's future prospects [5] - The company plans to repurchase shares worth between 20 million and 40 million yuan to support employee stock ownership plans and/or equity incentives [5]

Core Viewpoint - The Beijing Municipal Economic and Information Technology Bureau is set to launch a funding implementation guide aimed at supporting high-precision and cutting-edge industries, with a planned investment of over 1.5 billion yuan to cover more than 25 policy support directions by 2026 [1][3]. Group 1: Funding and Support Directions - The implementation guide focuses on addressing challenges in enterprise innovation and research and development, with nine key support areas designed to facilitate market validation for innovative products in fields such as robotics and integrated circuits [3]. - The guide includes support for the first demonstration applications of advanced materials and encourages commercial space enterprises to purchase insurance to mitigate innovation risks, providing up to 50% support of the enterprise's investment costs for qualifying projects [3][4]. Group 2: Growth and Development Initiatives - A "Win the Future" growth plan is introduced to support promising future industry projects with up to 10 million yuan in initial funding, alongside market institution co-investment and entrepreneurial guidance [4]. - The guide aims to enhance the growth of small and medium-sized enterprises (SMEs) by issuing service vouchers to reduce procurement costs for professional services and providing rewards for equity financing through the Beijing "Specialized, Refined, Characteristic, and Innovative" board [4]. Group 3: Strategic Implications - The implementation guide is designed to create a comprehensive policy framework that addresses core contradictions in industrial upgrading, thereby strengthening the ecosystem and sustainable development mechanisms for high-precision industries [5]. - The dual approach of policy content upgrading and efficiency enhancement is expected to solidify the technological foundation and ecological advantages of high-precision industries, supporting Beijing's goal of becoming a global benchmark city for the digital economy during the 14th Five-Year Plan period [5].

Core Viewpoint - Northeast Pharmaceutical is currently in a critical period of deep adjustment and transformation in the pharmaceutical industry, emphasizing the importance of each step in its development [1] Group 1: R&D and Strategic Transformation - Northeast Pharmaceutical is a significant drug production and export base in China, focusing on innovation-driven strategies and core business enhancement, achieving important results in R&D breakthroughs and quality improvement [2] - The company has increased R&D investment, aiming to accelerate the transition of innovative results from the laboratory to clinical applications [2] - The DCTY0801 injection, developed by its subsidiary, is set to undergo clinical trials for specific types of high-grade brain gliomas, marking a substantial breakthrough in cancer treatment innovation [2] - The acquisition of a 70% stake in DCTY0801's developer allows Northeast Pharmaceutical to quickly enter the cell therapy field, positioning it as a key platform for innovative drug development [3] - The company is committed to building a systematic and scalable talent cultivation system to enhance its R&D capabilities and facilitate its strategic shift from chemical pharmaceuticals to biological innovative drugs [3] Group 2: Quality Assurance and Market Expansion - Strong R&D capabilities provide essential support for product quality enhancement, which is crucial for global market competition [4] - The company’s core raw material product, Phosphomycin Amide, received the European Pharmacopoeia suitability certificate (CEP) in 2025, becoming the first domestic company to achieve this certification, enhancing its brand image and competitiveness in the international high-end market [4] - Northeast Pharmaceutical successfully passed a surprise inspection by the FDA, demonstrating its leading quality control system across the entire production and management chain [4] - The company is enhancing its quality management capabilities to support its expansion in both domestic and international markets [4] Group 3: Business Diversification and Value Enhancement - Northeast Pharmaceutical is expanding into related business areas, developing health food products based on the concept of "medicinal food homology" and launching a skincare brand, "Qifangyuan," to enter the beauty market [6] - The company’s diversification efforts are based on professional technology and aim to extend the value chain around the core of "health" [6] - The "Qifangyuan" brand integrates pharmaceutical technology and standards into skincare product development, showcasing the company's innovative approach [6] - Northeast Pharmaceutical is committed to optimizing its health product matrix and exploring comprehensive health services to create additional growth points [6] Group 4: Recognition and Achievements - The company’s improved business layout and solid operational results have enhanced its overall strength, leading to recognition from various sectors [7] - In 2025, Northeast Pharmaceutical was included in the list of recommended "National Intellectual Property Demonstration Enterprises" in Liaoning Province and re-certified as a national high-tech enterprise [7] - The company received the title of "Top 100 Pharmaceutical Industrial Enterprises by Revenue" for the 2024-2025 period in industry evaluations [7]